<DOC>
	<DOC>NCT00043342</DOC>
	<brief_summary>The purpose of this research study is to evaluate the safety, tolerability, and efficacy of Interferon gamma-1b (IFN-gamma 1b) when administered by subcutaneous injection over a period of 4 weeks to patients with mild-to-moderate cystic fibrosis. Additionally, preliminary assessments on the effects of IFN-gamma 1b on lung function and other indicators of health will be made.</brief_summary>
	<brief_title>Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>At least 6 years of age Diagnosis of cystic fibrosis (against certain criteria) Able to perform pulmonary (lung) function tests and participate in induced sputum procedures Pulmonary function values must meet certain minimal requirements Must have acceptable laboratory test results Cannot be on certain medications during and immediately prior to study Cannot have a history of unstable or deteriorating cardiac or neurologic disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>pulmonary impairment</keyword>
</DOC>